Which intramuscular medication is appropriate for treating acute migraine with nausea in an adult patient in a clinic setting?

IM Medications for Acute Migraine with Nausea in Clinic Setting

For acute migraine with nausea in a clinic setting, give intramuscular sumatriptan 6 mg subcutaneously (or IM if SC not feasible) combined with an antiemetic such as metoclopramide 10 mg IM or prochlorperazine 10 mg IM. 1

Primary Recommendation: Nonoral Triptan + Antiemetic

The 2025 American College of Physicians guidelines explicitly recommend using a nonoral triptan with an antiemetic in patients with severe nausea or vomiting 1. This addresses both the migraine pain and the nausea that prevents oral medication absorption.

Specific Injectable Options:

For Migraine Pain:

• Sumatriptan 6 mg subcutaneous (can be given IM if SC route unavailable) - This has the strongest evidence base with multiple class I studies demonstrating efficacy 2, 3
• Available as auto-injector or standard injection
• Onset within 10-15 minutes
• Contraindicated in patients with cardiovascular disease, uncontrolled hypertension, or hemiplegic migraine

For Nausea:

• Prochlorperazine 10 mg IM - Has multiple class I studies and is rated "must offer" (Level A) in the 2025 American Headache Society guidelines 3
• Metoclopramide 10 mg IM - Also has strong evidence (Level B "should offer") 2, 3
• Both provide dual benefit: antiemetic effect plus independent antimigraine properties

Alternative IM Options

If triptans are contraindicated or unavailable:

Dopamine Antagonists Alone:

• Prochlorperazine 10 mg IM - Highly likely to be effective based on multiple class I studies 3
• Metoclopramide 10 mg IM - Likely effective based on class I evidence 3
• Both treat migraine pain AND nausea simultaneously
• Watch for akathisia (restlessness) and dystonic reactions; consider diphenhydramine 25-50 mg IM prophylactically

NSAIDs:

• Ketorolac 30-60 mg IM - Rated "should offer" (Level B) in 2025 guidelines 3
• Dexketoprofen IV (if IV access available) - Highly likely effective 3
• Less effective than dopamine antagonists but safer side effect profile

What NOT to Use

Avoid opioids (hydromorphone, morphine) - The 2025 ACP guidelines explicitly state "do not use opioids" for acute migraine 1. The 2025 AHS guidelines rate hydromorphone as "must not offer" (Level A) based on class I evidence showing it is likely ineffective 3.

Avoid butalbital compounds - Explicitly not recommended by ACP guidelines 1

Clinical Pearls

• Timing matters: Administer as early as possible in the migraine attack for best efficacy 1
• Combination therapy is superior: The evidence consistently shows combining treatments (triptan + antiemetic) works better than monotherapy 1
• Monitor for medication overuse headache: Triptans should not be used more than 10 days per month 1
• Consider cardiovascular screening before triptan use in patients with vascular risk factors
• Antiemetic side effects: Have diphenhydramine available for extrapyramidal symptoms from dopamine antagonists

Practical Algorithm

1. First-line: Sumatriptan 6 mg SC/IM + Prochlorperazine 10 mg IM (or Metoclopramide 10 mg IM)
2. If triptan contraindicated: Prochlorperazine 10 mg IM or Metoclopramide 10 mg IM alone
3. If dopamine antagonists contraindicated: Ketorolac 30-60 mg IM + oral/rectal antiemetic if tolerated
4. Never use: Opioids or butalbital

This approach is based on the most recent 2025 guidelines from both the American College of Physicians 1 and the American Headache Society 3, which represent the highest quality evidence available for acute migraine management in outpatient settings.